drugset / Trial / NCT01341457
A Study of LY2603618 in Combination With Gemcitabine in Participants With Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of this study is to evaluate the safety and tolerability of LY2603618 in combination with the standard dose of gemcitabine up to the global recommended dose of LY2603618 in Japanese participants with solid advanced or metastatic tumors.
Timeline
- Start
- 2011-05
- Primary completion
- 2013-06
- Completion
- 2016-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RABUSERTIB | Small molecule | 170 mg | Intravenous |
| Subject | RABUSERTIB | Small molecule | 230 mg | Intravenous |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |